Steven W Sanders
Pharmacy in Salt Lake City, UT
License number
Utah 268098-8912
Issued Date
Sep 28, 1993
Expiration Date
May 31, 1999
Category
Pharmacy
Type
Limited Controlled Substance-Individual
Address
Address
Salt Lake City, UT
Professional information
Compositions And Methods For Minimizing Adverse Drug Experiences Associated With Oxybutynin Therapy
US Patent:
6743441, Jun 1, 2004
Filed:
Mar 15, 2002
Appl. No.:
10/098752
Inventors:
Steven W. Sanders - Salt Lake City UT
Charles D. Ebert - Salt Lake City UT
Charles D. Ebert - Salt Lake City UT
Assignee:
Watson Pharmaceuticals, Inc. - Corona CA
International Classification:
A61F 1302
US Classification:
424448, 424449, 424422, 424434
Abstract:
The present invention provides compositions and methods for administering oxybutynin while minimizing the incidence and or severity of adverse drug experiences associated with oxybutynin therapy. In one aspect, these compositions and methods provide a lower plasma concentration of oxybutynin metabolites, such as N-desethyloxybutynin, which is presumed to be contributing at least in part to some of the adverse drug experiences, while maintaining sufficient oxybutynin plasma concentration to benefit a subject with oxybutynin therapy. The invention also provides isomers of oxybutynin and its metabolites that meet these characteristics of minimized incidence and/or severity of adverse drug experiences, and maintenance of beneficial and effective therapy for overactive bladder.
Unoccluded Topical Oxybutynin Gel Composition And Methods For Transdermal Oxybutynin Therapy
US Patent:
8241662, Aug 14, 2012
Filed:
Dec 21, 2006
Appl. No.:
11/645076
Inventors:
Charles D. Ebert - Salt Lake City UT, US
Steven W. Sanders - Salt Lake City UT, US
Steven W. Sanders - Salt Lake City UT, US
Assignee:
Watson Laboratories, Inc. - Salt Lake City UT
International Classification:
A61F 13/00, A61F 13/02, A61L 15/16, A61K 9/70
US Classification:
424449, 424448, 424443
Abstract:
The present invention provides compositions and methods for administering oxybutynin while minimizing the incidence and or severity of adverse drug experiences associated with oxybutynin therapy. In one aspect, these compositions and methods provide a lower plasma concentration of oxybutynin metabolites, such as N-desethyloxybutynin, which is presumed to be contributing at least in part to some of the adverse drug experiences, while maintaining sufficient oxybutynin plasma concentration to benefit a subject with oxybutynin therapy. The invention also provides isomers of oxybutynin and its metabolites that meet these characteristics of minimized incidence and/or severity of adverse drug experiences, and maintenance of beneficial and effective therapy for overactive bladder. In some aspects, the composition may be presented in the form of an unoccluded or free form topically administered gel.
Compositions And Methods For Minimizing Adverse Drug Experiences Associated With Oxybutynin Therapy
US Patent:
7081250, Jul 25, 2006
Filed:
Dec 8, 2003
Appl. No.:
10/731040
Inventors:
Steven W. Sanders - Salt Lake City UT, US
Charles D. Ebert - Salt Lake City UT, US
Charles D. Ebert - Salt Lake City UT, US
Assignee:
Watson Laboratories, Inc. - Salt Lake City UT
International Classification:
A61F 13/00
US Classification:
424449, 424448
Abstract:
The present invention provides compositions and methods for administering oxybutynin while minimizing the incidence and or severity of adverse drug experiences associated with oxybutynin therapy. In one aspect, these compositions and methods provide a lower plasma concentration of oxybutynin metabolites, such as N-desethyloxybutynin, which is presumed to be contributing at least in part to some of the adverse drug experiences, while maintaining sufficient oxybutynin plasma concentration to benefit a subject with oxybutynin therapy. The invention also provides isomers of oxybutynin and its metabolites that meet these characteristics of minimized incidence and/or severity of adverse drug experiences, and maintenance of beneficial and effective therapy for overactive bladder.
Compositions And Methods For Transdermal Oxybutynin Therapy
US Patent:
2003012, Jul 3, 2003
Filed:
Nov 1, 2002
Appl. No.:
10/286346
Inventors:
Charles Ebert - Salt Lake City UT, US
Steven Sanders - Salt Lake City UT, US
Steven Sanders - Salt Lake City UT, US
Assignee:
Watson Pharmaceuticals, Inc.
International Classification:
A61K009/70, A61K031/24
US Classification:
424/449000, 514/540000
Abstract:
The present invention provides compositions and methods for administering oxybutynin while minimizing the incidence and or severity of adverse drug experiences associated with oxybutynin therapy. In one aspect, these compositions and methods provide a lower plasma concentration of oxybutynin metabolites, such as N-desethyloxybutynin, which is presumed to be contributing at least in part to some of the adverse drug experiences, while maintaining sufficient oxybutynin plasma concentration to benefit a subject with oxybutynin therapy. The invention also provides isomers of oxybutynin and its metabolites that meet these characteristics of minimized incidence and/or severity of adverse drug experiences, and maintenance of beneficial and effective therapy for overactive bladder.
Compositions And Methods For Minimizing Adverse Drug Experiences Associated With Oxybutynin Therapy
US Patent:
7081249, Jul 25, 2006
Filed:
Dec 8, 2003
Appl. No.:
10/731039
Inventors:
Steven W. Sanders - Salt Lake City UT, US
Charles D. Ebert - Salt Lake City UT, US
Charles D. Ebert - Salt Lake City UT, US
Assignee:
Watson Laboratories, Inc. - Salt Lake City UT
International Classification:
A61F 13/00
US Classification:
424449, 424448
Abstract:
The present invention provides compositions and methods for administering oxybutynin while minimizing the incidence and or severity of adverse drug experiences associated with oxybutynin therapy. In one aspect, these compositions and methods provide a lower plasma concentration of oxybutynin metabolites, such as N-desethyloxybutynin, which is presumed to be contributing at least in part to some of the adverse drug experiences, while maintaining sufficient oxybutynin plasma concentration to benefit a subject with oxybutynin therapy. The invention also provides isomers of oxybutynin and its metabolites that meet these characteristics of minimized incidence and/or severity of adverse drug experiences, and maintenance of beneficial and effective therapy for overactive bladder.
Compositions And Methods For Transdermal Oxybutynin Therapy
US Patent:
7029694, Apr 18, 2006
Filed:
Nov 1, 2002
Appl. No.:
10/286381
Inventors:
Charles D. Ebert - Salt Lake City UT, US
Steven W. Sanders - Salt Lake City UT, US
Steven W. Sanders - Salt Lake City UT, US
Assignee:
Watson Laboratories, Inc. - Salt Lake City UT
International Classification:
A61F 13/00, A61F 13/02, A61K 15/16
US Classification:
424449, 424443, 424448
Abstract:
The present invention provides compositions and methods for administering oxybutynin while minimizing the incidence and or severity of adverse drug experiences associated with oxybutynin therapy. In one aspect, these compositions and methods provide a lower plasma concentration of oxybutynin metabolites, such as N-desethyloxybutynin, which is presumed to be contributing at least in part to some of the adverse drug experiences, while maintaining sufficient oxybutynin plasma concentration to benefit a subject with oxybutynin therapy. The invention also provides isomers of oxybutynin and its metabolites that meet these characteristics of minimized incidence and/or severity of adverse drug experiences, and maintenance of beneficial and effective therapy for overactive bladder. In some aspects, the composition may be presented in the form of an unoccluded or free form topically administered gel.
Compositions And Methods For Transdermal Oxybutynin Therapy
US Patent:
7179483, Feb 20, 2007
Filed:
Aug 6, 2004
Appl. No.:
10/913019
Inventors:
Charles D. Ebert - Salt Lake City UT, US
Steven W. Sanders - Salt Lake City UT, US
Steven W. Sanders - Salt Lake City UT, US
Assignee:
Watson Pharmaceuticals, Inc. - Corona CA
International Classification:
A61F 13/00, A61F 13/02, A61L 15/16
US Classification:
424449, 424448, 424443
Abstract:
The present invention provides compositions and methods for administering oxybutynin while minimizing the incidence and or severity of adverse drug experiences associated with oxybutynin therapy. In one aspect, these compositions and methods provide a lower plasma concentration of oxybutynin metabolites, such as N-desethyloxybutynin, which is presumed to be contributing at least in part to some of the adverse drug experiences, while maintaining sufficient oxybutynin plasma concentration to benefit a subject with oxybutynin therapy. The invention also provides isomers of oxybutynin and its metabolites that meet these characteristics of minimized incidence and/or severity of adverse drug experiences, and maintenance of beneficial and effective therapy for overactive bladder. In some aspects, the composition may be presented in the form of an unoccluded or free form topically administered gel.
Compositions And Methods For Minimizing Adverse Drug Experiences Associated With Oxybutynin Therapy
US Patent:
7087241, Aug 8, 2006
Filed:
Oct 7, 2005
Appl. No.:
11/246558
Inventors:
Steven W. Sanders - Salt Lake City UT, US
Charles D. Ebert - Salt Lake City UT, US
Charles D. Ebert - Salt Lake City UT, US
Assignee:
Watson Laboratories, Inc. - Salt Lake City UT
International Classification:
A61F 13/00, A61F 13/02, A61L 15/16
US Classification:
424449, 424448, 424434, 424435, 424422
Abstract:
The present invention provides compositions and methods for administering oxybutynin while minimizing the incidence and or severity of adverse drug experiences associated with oxybutynin therapy. In one aspect, these compositions and methods provide a lower plasma concentration of oxybutynin metabolites, such as N-desethyloxybutynin, which is presumed to be contributing at least in part to some of the adverse drug experiences, while maintaining sufficient oxybutynin plasma concentration to benefit a subject with oxybutynin therapy. The invention also provides isomers of oxybutynin and its metabolites that meet these characteristics of minimized incidence and/or severity of adverse drug experiences, and maintenance of beneficial and effective therapy for overactive bladder.
Compositions And Methods For Minimizing Adverse Drug Experiences Associated With Oxybutynin Therapy
US Patent:
7081252, Jul 25, 2006
Filed:
Dec 8, 2003
Appl. No.:
10/731824
Inventors:
Steven W. Sanders - Salt Lake City UT, US
Charles D. Ebert - Salt Lake City UT, US
Charles D. Ebert - Salt Lake City UT, US
Assignee:
Watson Laboratories, Inc. - Salt Lake City UT
International Classification:
A61F 13/00
US Classification:
424449, 424448
Abstract:
The present invention provides compositions and methods for administering oxybutynin while minimizing the incidence and or severity of adverse drug experiences associated with oxybutynin therapy. In one aspect, these compositions and methods provide a lower plasma concentration of oxybutynin metabolites, such as N-desethyloxybutynin, which is presumed to be contributing at least in part to some of the adverse drug experiences, while maintaining sufficient oxybutynin plasma concentration to benefit a subject with oxybutynin therapy. The invention also provides isomers of oxybutynin and its metabolites that meet these characteristics of minimized incidence and/or severity of adverse drug experiences, and maintenance of beneficial and effective therapy for overactive bladder.
Compositions And Methods For Transdermal Oxybutynin Therapy
US Patent:
2009001, Jan 15, 2009
Filed:
Sep 24, 2008
Appl. No.:
12/236585
Inventors:
Charles D. Ebert - Salt Lake City UT, US
Steven W. Sanders - Salt Lake City UT, US
Steven W. Sanders - Salt Lake City UT, US
International Classification:
A61K 31/216, A61P 13/10
US Classification:
514534
Abstract:
The present invention provides compositions and methods for administering oxybutynin while minimizing the incidence and or severity of adverse drug experiences associated with oxybutynin therapy. In one aspect, these compositions and methods provide a lower plasma concentration of oxybutynin metabolites, such as N-desethyloxybutynin, which is presumed to be contributing at least in part to some of the adverse drug experiences, while maintaining sufficient oxybutynin plasma concentration to benefit a subject with oxybutynin therapy. The invention also provides isomers of oxybutynin and its metabolites that meet these characteristics of minimized incidence and/or severity of adverse drug experiences, and maintenance of beneficial and effective therapy for overactive bladder. In some aspects, the composition may be presented in the form of an unoccluded or free form topically administered gel.